Comment: Increasing constitutional challenges to US FTC adjudication could hasten Supreme Court review
Following Amgen and Horizon Therapeutics’ recent counterclaim against the US Federal Trade Commission alleging the agency’s in-house court violates the Constitution, a blueprint has emerged for dealmakers to challenge the constitutionality...To view the full article, register now.
Already a subscriber? Click here to view full article